Compare AbbVie Inc (ABBV) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs iShares Bitcoin Trust — how do they compare? AbbVie Inc trades at $252.67 (market cap $449.91B), while iShares Bitcoin Trust trades at $35.28. The key difference: AbbVie Inc pays a 2.72% dividend while iShares Bitcoin Trust pays none, and AbbVie Inc is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| ABBV | IBIT | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Crypto-linked |
52-Week High | $261.07 | $71.29 |
52-Week Low | $184.85 | $33.29 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.61, down 0.84% on the day, with a bullish technical outlook supported by moving averages and strong support at $248. The company reported revenue of $61.16B in 2025, with EPS beats in recent quarters, though net income margin has trended down to 5.79%. Key growth drivers Skyrizi and Rinvoq are offsetting Humira declines, with positive clinical updates like the Phase 2 ELAHERE data at SGO 2026.
The stock offers a compelling buy case with a consensus price target of $266.33 (5.4% upside) and strong analyst support (68% buy ratings). However, risks include patent cliffs in the 2030s, high debt levels, and margin pressure. Dividend growth is recovering, supporting income investors, but execution on pipeline assets remains critical for sustained expansion.
IBIT trades at $36.12, up 3.58% today, with a bullish technical signal despite bearish moving averages. Key support lies at $35 and resistance at $37. The stock faces headwinds from sector volatility and significant ETF outflows, as reported by Zacks Investment Research on 2026-07-06. Recent news highlights competitive pressures among Bitcoin ETFs, with IBIT leading in assets under management according to The Motley Fool on 2026-06-29.
The outlook remains cautious due to market sentiment shifts and regulatory uncertainties. Investment opportunities hinge on the company's ability to maintain its asset scale advantage, while risks include continued investor outflows and broader crypto market declines impacting related equities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
